| Page 58 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis

Author(s): 
Armin Rashidi, Mohamad A Meybodi, Wenhao Cao, Haitao Chu, Erica D Warlick, Steven Devine, Marcelo C Pasquini, Daniel J Weisdorf, Mehdi Hamadani
Primary Author: 
Armin Rashidi
Journal Title: 
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation
Original Publication Date: 
Jun 2020

In a systematic review and meta-analysis, we compared allogeneic transplant outcomes after myeloablative conditioning (MAC) versus reduced-intensity conditioning (RIC) in patients with

Bone Marrow Disease(s): 

SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes

Author(s): 
Qing Zhang, Mintallah Haider, Najla H Al Ali, Jeffrey E Lancet, Pearlie K Epling-Burnette, Alan F List, Eric Padron, Rami S Komrokji
Primary Author: 
Qing Zhang
Journal Title: 
Clinical Lymphoma , Myeloma & Leukemia
Original Publication Date: 
Jun 2020

Background: Immunosuppressive therapy (IST) yields durable hematologic improvement (HI) in a subset of patients with lower-risk myelodysplastic syndrome (MDS). Age,

Bone Marrow Disease(s): 

To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia

Author(s): 
David A Sallman
Primary Author: 
David A Sallman
Journal Title: 
Haematologica
Original Publication Date: 
Jun 2020
Bone Marrow Disease(s): 

Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study

Author(s): 
Shyamala C Navada, Guillermo Garcia-Manero, Rosalie OdchimarReissig, Naveen Pemmaraju, Yesid Alvarado, Maro N Ohanian, Rosmy B John, Erin P Demakos, Patrick S Zbyszewski, Manoj Maniar, Richard C Woodman, Steven M Fruchtman, Lewis R Silverman
Primary Author: 
Shyamala C Navada
Journal Title: 
Leukemia Research
Original Publication Date: 
Jul 2020

Phase 1 results from a Phase 1/2 study comprise 18 patients with

Bone Marrow Disease(s): 

Iron Overload Alters the Energy Metabolism in Patients With Myelodysplastic Syndromes: Results From the Multicenter FISM BIOFER Study

Author(s): 
Daniela Cilloni, Silvia Ravera, Chiara Calabrese, Valentina Gaidano, Pasquale Niscola, Enrico Balleari, Daniela Gallo, Jessica Petiti, Elisabetta Signorino, Valentina Rosso, Cristina Panuzzo, Federica Sabatini, Giacomo Andreani
Primary Author: 
Daniela Cilloni
Journal Title: 
Scientific Reports
Original Publication Date: 
Jun 2020

Bone Marrow Disease(s): 

High Serum Ferritin Levels in Newly Diagnosed Patients With Myelodysplastic Syndromes Are Associated With Greater Symptom Severity

Author(s): 
Giovanni Caocci, Marco Vignetti, Andrea Patriarca, Massimo Breccia, Uwe Platzbecker, Giuseppe A Palumbo, Reinhard Stauder, Francesco Cottone, Duska Petranovic, Maria Teresa Voso, Agostino Tafuri, Rosangela Invernizzi, Jo Caers
Primary Author: 
Giovanni Caocci
Journal Title: 
International Journal of Hematology
Original Publication Date: 
Jun 2020

We examined the association between serum

Bone Marrow Disease(s):